Xiidra (Lifitegrast)
- Region
- 🇪🇺 EU
- Active substance
- Lifitegrast
- Company
- Novartis Europharm Limited
- Status
- Application withdrawn
- Therapeutic area
- Dry Eye Syndromes
- Application
- EMEA/H/C/004653
- ATC
- S01XA25
- Official record
- www.ema.europa.eu
Indication
Treatment of moderate to severe dry eye disease in adults for whom prior artificial tears has not been sufficient
Regulatory milestones
No milestones recorded in the last year.
Follow Xiidra
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.